Meet the leaders and members of the Translational Therapeutics research program at the OSUCCC – James who take basic science research from bench to bedside, turning cancer discoveries into clinical trials.

Leaders

David Carbone, MD, PhD

Dr. Carbone is an expert in the molecular genetics of lung tumors, which includes understanding the specific cells and genetic markers in each patient’s lung cancer and developing treatments and drugs that target specific tumor cells. His research interests, grant support and publications focus on.

Read More

Quintin Pan, PhD

Dr. Pan’s research is focused on understanding the genetic determinants of aggressive head and neck cancer. His laboratory is interested in identifying "druggable" genes/targets, to understand how these genes function in the context of head and neck cancer development and progression, and to.

Read More

Members

Leona Ayers, MD

Dr. Ayers has a long-term interest in the pathology of infectious diseases and recently a focused interest in infectious agents and malignancy. She is the principle investigator for the Mid-region AIDS and Cancer Specimen Resource (ACSR), a project of the NCI AIDS Malignancy Program.

Read More

Xue-feng Bai, MD, PhD

Dr. Bai's laboratory studies the pathogenic mechanisms in immune-mediated diseases. They are particularly interested in T lymphocyte responses in autoimmune diseases and cancer.

Read More

Sujit Basu, MD, PhD

Dr. Basu also has a Joint Professor appointment in the Division of Medical Oncology, Department of Internal Medicine. His research looks into the role of the endogenous factors regulating tumor microenvironment including tumor neovascularization and development of new therapy.

Read More

Erica Bell, PhD

Dr. Bell's primary research focus is to understand the mechanisms of radiation and chemotherapy resistance and sensitivity. Her research areas are correlative analysis on clinical trial tissue including genomic, epigenomic, transcriptomic, and proteomic profiling, with an emphasis on brain and.

Read More

William Carson, III, MD

Dr. Carson is a surgical oncologist with clinical interests in breast cancer, melanoma and general cancer surgery. His primary research focus is the immunotherapy of tumors, which can be thought of as using drugs and other treatments to boost the human immune system's innate ability to fight tumor.

Read More

Arnab Chakravarti, MD

I am professor and chair of the Department of Radiation Oncology at The Ohio State University, where I also hold the Max Morehouse Chair of Cancer Research and direct the Brain Tumor Program. In addition, I am a member of the Translational Therapeutics Program at Ohio State’s Comprehensive Cancer.

Read More

Jeffrey Chalmers, PhD

The research in Dr. Chalmer's labs involves the development of fundamental understanding and applications of the interaction of hydrodynamic and magnetic forces and cells. This work can range from the development of fundamental mathematical relationships describing physical phenomena to the.

Read More

James Chen, MD

Dr. Chen’s research explores how translational bioinformatics can be applied to cancer. Specifically, he uses high-throughput genomics to identify molecular pathway deregulations and to predict clinical responses to targeted therapies.

Read More

David Cohn, MD

My research focus includes identification of novel biomarkers in ovarian cacner for early detection and prevention. We have investigated the role of micrRNA from blood as a biomarker for ovarian cancer, and have developed a vaccine targeting pro-angiogenic molecules in this disease.

Read More

Kevin Coombes, PhD

Dr. Coombes's current research focuses in statistical, mathematical, and computational methods to process, analyze, and understand highly multivariate biological data arising from high throughput technologies. He is particularly interested in (1) methods that incorporate existing biological.

Read More

Timothy Cripe, MD, PhD

My laboratory is interested in developing and studying targeted therapeutics for non-CNS solid tumors in children, particularly sarcomas and neuroblastoma. Our efforts are primarily focused on the development of oncolytic virotherapy as well as small molecule targeted inhibitors.

Read More

Mikhail Dikov, PhD

Dr. Dikov’s research broadly relates to the tumor-host interaction, cancer immunology, cancer biology, and tumor microenvironment. Specifically, it is focused on the role of tumor-derived factors in hematopoietic development, immune cell differentiation and function.

Read More

Mary Dillhoff, MD

Dr. Dillhoff is a surgical oncologist with a research interest in upper gastrointestinal, hepatobiliary cancers and neuroendocrine tumors. She performs clinical research in these areas as well as basic science research with collaborators.

Read More

Yizhou Dong, PhD

Dr Dong’s interest is in regulating multiple key signaling pathways in cancer via combination of RNA, DNA and small molecules. Screening of diverse combinations will lead to the optimal therapeutic regimen for cancer therapy.

Read More

Wenrui Duan, PhD

(1) Targeting cancer cells containing mutant p53: p53 mutations are reported in 50-60% of non-small cell lung cancers and in up to 90% of small cell tumors, thus p53 represent a common mutation in this malignancy. Studies have shown that restoring wild type p53 function leads to regression of.

Read More

Joelle Fenger, DVM, PhD, ACVIM

As a veterinary oncologist, Dr. Fenger’s work using spontaneous models of cancer in dogs has focused on the comparative biology of canine and human cancers with the goal of identifying common molecular pathways that provide a foundation for translational clinical trials. Her lab previously.

Read More

Jonathan Finlay, MD

Dr. Finlay is an academic pediatric oncologist whose professional focus for over 35 years has been on improving outcomes for children, adolescents and young adults with brain cancer. Since 1991, he have initiated, conducted, completed and published results of six sequential multi-national.

Read More

Julie Gastier-Foster, PhD

Dr. Gastier-Foster is responsible for the oversight of the Cytogenetics/Molecular Genetics Laboratory, COG ALL Reference Laboratory and Bank, COG Neuroblastoma Laboratory, COG Wilms Tumor Reference Laboratory, and the COG and SWOG Leukemia Banks. Additionally, Dr. Gastier-Foster serves as the.

Read More

Kalpana Ghoshal, PhD

Dr. Goshal’s lab focuses on elucidating the functions of microRNAs and the factors involved in DNA methylation / hydroxymethylation in liver biology and the consequence of their deregulation in liver disease such as alcoholic and nonalcoholic fatty liver disease, drug-induced liver toxicity and

Read More

Pierre Giglio, MD

Dr. Giglio research involves developing clinical trials in neuro-oncology with a focus on newly diagnosed and recurrent glioblastoma. More specifically, he is interested in novel clinical trial design and targeted therapies for the treatment of patients with these tumors.

Read More

Rajgopal Govindarajan, DVM, PhD

Dr. Govindarajan’s laboratory is interested in understanding and overcoming drug resistance in pancreatic cancer. His training is in the areas of animal sciences, cancer biology and drug transport-based pharmacokinetics, and has extensively used cell and animal models to evaluate nucleoside and.

Read More

Deliang Guo, PhD

Dr. Guo's lab's long term goal is to determine the key molecular targets in cancer metabolism and translate it to clinic. The lab's detailed research interests are to: 1) Investigate the molecular link between oncogenic signaling PI3K/Akt and Ras/MEK/ERK signaling with cancer.

Read More

Peixuan Guo, PhD

Dr. Guo’s major research interest is to apply RNA nanotechnology for cancer therapy. His lab has developed multifunctional RNA nanoparticles harboring RNA aptamer, siRNA, anti-miRNA, drugs or ribozymes.

Read More

Nathan Hall, MD, PhD

The main focus of Dr. Hall’s efforts involve utilizing molecular imaging techniques to improve the management and care of cancer patients. Projects involve improving quantification for therapy response assessment, as well as, developing imaging techniques for use in the intra and perioperative.

Read More

Philip Hart, MD

As a medical pancreatologist, Dr. Hart evaluates and manages patients with the spectrum of benign to malignant pancreatic disorders. Cancer-specific research interests include further understanding the relationship between new-onset diabetes mellitus and pancreatic cancer, as well as early.

Read More

John Hays, MD, PhD

Dr. Hays' research focuses on using proteomics based approaches to determine functionally significant signaling nodes within the tumor and the tumor microenvironment using in vitro based cell culture and co-culture systems. Dr. Hays has identified a number of phosophorylated signaling proteins

Read More

Xiaoming (Shawn) He, PhD

The research in my lab has been focused on developing (1) novel micro and nano scale biomaterials and systems with great biocompatibility for improved drug, gene, cell, and tissue delivery and (2) energy-based approaches (using both cold and heat generated with microwave, radio frequency, laser,

Read More

Zhiwei Hu, MD, PhD

Dr. Hu is one of first few scientists who proposed to target both the tumor cells and tumor neovasculature for development of novel dual neovascular- and cancer cell-targeted therapy for cancer. The Icon that Dr. Hu co-invented is one such dual-targeting agent.

Read More

Naduparambil Jacob, PhD

My research focus/areas of interests include: a) Biomarkers for early prediction of the delayed effects of normal tissue injury following radiation disaster or therapeutic exposure: The ultimate goal is to develop non-invasive serum/urine based biodosimetry and therapeutic strategies for

Read More

Samson Jacob, PhD

Dr. Jacob’s research program focuses on three areas: (1) Epigenetic silencing of tumor suppressors at different stages of tumorigenesis using cells in culture and animal models with emphasis on mechanisms and therapeutic interventions in human cancer; (2) Delineating the role of microRNAs in the

Read More

Joanne Jeter, MD

Dr. Jeter’s primary research interest is in improving the identification and management of individuals at hereditary risk of cancer. Her clinical practice focuses on patients with germline mutations predisposing to many types of cancer, including breast, ovarian, colon, and skin cancers.

Read More

Selvendiran Karuppaiyah, PhD

As a member of the Translational Therapeutics Program at OSUCCC – James, Selvendiran Karuppaiyah, PhD, focuses on ovarian and lung neoplasms, disease models and hepatocellular carcinoma. He also researches reperfusion injury, myocardial infarction and hypertension.

Read More

Pravin Kaumaya, PhD

Dr. Kaumaya investigates how patients’ immune systems can be directed to recognize and kill their own cancer cells

Read More

Balveen Kaur, PhD

Dr. Kaur’s laboratory is focused on the development of oncolytic viral therapies. Interests include immunomodulation, antiangiogenic strategies, and tumor microenvironment.

Read More

Michael Knopp, MD, PhD

The broad research activities focus on imaging biomarker for disease characterization and response assessment, imaging technology development and validation, imaging biomarker development and validation.

Read More

Pawan Kumar, PhD

Dr. Kumar's research focuses on exploring the microbial etiology of oral cancer, with special emphasis on high risk cohorts, for example, smokers. Dr. Kumar's lab uses metagenomic and metatranscritptomic approaches to examine host-microbial interactions.

Read More

Albert Lai, PhD

Dr. Lai's research focuses on extracting and characterizing phenotype data from the electronic medical record of patients with samples in biorepositories to support retrieval of highly specifically defined specimens collected from patients. The development and evaluation of such technologies and.

Read More

Norman Lehman, MD, PhD

Dr. Lehman's interests are in cell cycle and apoptosis regulators as targets for cancer chemotherapy. His lab also studies aspects of cell signalling in tumor angiogenesis.

Read More

Cheryl London, DVM, PhD

Dr. London's research includes the use of spontaneous tumors in dogs and cats as models for human cancer, investigation of kinase dysfunction in animal tumors, and mouse models of Kit dysregulation

Read More

Thomas Mace, PhD

The goal of my research laboratory is to discover factors and pathways that promote immunosuppression and enhance ant-tumor immunity in gastrointestinal malignancies and diseases (i. e.

Read More

Elaine Mardis, PhD

I am interested in cancer genomics, both from a discovery and a translational point of view. This goes to determining common driver mutations/genes and pathways that can cause cancer to develop and progress, and can tell us the best therapeutic approaches to fight these cancers on an individual.

Read More

Anne Noonan, MB, BCh

Dr. Noonan's research includes developing new therapies for solid tumors, in particular for hepatocellular carcinoma due to solid tumors (e. g.

Read More

Michael Oglesbee, DVM, PhD

Cellular heat shock proteins (HSPs) are known for their support of viral gene expression, and for influencing innate and adaptive immune responses, yet nothing is known about how virus-HSP interaction may influence viral virulence. Our laboratory uses the mouse model of measles virus (MeV).

Read More

David O'Malley, MD

We continue to work toward improving improving outcomes in the treatment of gynecologic cancers by novel and innovative therapies. Our goal is to not only improve survival but also to improve quality of life.

Read More

Gregory Otterson, MD

Dr. Otterson is broadly interested in improving the care and understanding of thoracic malignancies (adenocarcinoma, squamous carcinoma, large cell carcinoma, never-smoking adenocarcinoma, small cell lung cancer, mesothelioma and thymic cancers). His research centers around the genetic and.

Read More

Navjot Pabla, PhD

Dr. Pabla’s laboratory is focused on identifying therapeutic targets for kidney diseases. Acute kidney injury and renal cell carcinoma are the two major areas of interest.

Read More

Kamalakannan Palanichamy, PhD

Dr. Palanichamy's research includes: Identifying Underlying Mechanisms of Radiation Resistance in Treatment Refractory Tumors, Cancer Stem Cells, Exploiting Protein-Protein Interactions at Transcriptional and Translational Level and Identifying New Therapeutic Targets, and Integrative OMICS

Read More

Kyle Perry, MD

Dr. Perry’s cancer-relevant research interests include cancer prevention through treatment of Barrett’s Esophagus (BE), and prevention, surgical treatment, and outcome improvement of esophageal cancer (ECA), gastric cancer, and pancreatic cancer. His cancer research interest extends from.

Read More

Raphael Pollock, MD, PhD

Dr. Pollock is a member of the Translational Therapeutics team at OSUCCC – James, where his focuses his research on soft-tissue sarcoma, a rare cancer in adults but prevalent in children. The laboratory research agenda is organized around studies of soft tissue sarcoma histologic subtypes.

Read More

Vinay Puduvalli, MD

Dr. Puduvalli's academic interests are directed towards patient oriented research in preclinical, translational and clinical studies. He has initiated a comprehensive effort to study epigenetic modulation of targeted therapies against malignant gliomas.

Read More

Bhuvaneswari Ramaswamy, MD

As a clinical researcher in Hematology/Oncology, Dr. Ramaswamy is investigating new methods to identify which breast tumors are resistant to hormone therapy. By understanding what makes theses tumors resistant, researchers may be able to develop alternative therapies.

Read More

Nilsa Ramirez-Milan, MD

Dr. Nilsa Ramirez is an anatomic pathologist with subspecialty training in gynecologic and obstetrical pathology, as well as an associate professor of pathology. She is knowledgeable and experienced in the histopathologic diagnosis of tumors, and in the technology of preserving tissues for.

Read More

Raju Raval, MD, DPhil

I am an Assistant Professor of Radiation Oncology at OSU focusing on CNS malignancies. I completed my doctorate in molecular oncology at the University of Oxford, medical school at the University of Pennsylvania, and Radiation Oncology residency at John Hopkins.

Read More

James Rocco, MD, PhD

Dr. Rocco focuses on the surgical care and regular surveillance of the head and neck cancer patient. He is also experienced in helping select head and neck cancer patients to participate with ongoing clinical trials.

Read More

Sameek Roychowdhury, MD, PhD

Sameek Roychowdhury, MD, PhD, is a member of the Translational Therapeutics Program at OSUCCC – James, where he is working to identify putative predictive genomic biomarkers for targeted therapies and to understand resistance mechanisms for those therapies. His research involves translating.

Read More

Wolfgang Sadee, Dr.rer.nat

I am a member of the Translational Therapeutics Program at the OSUCCC – James, where my research focuses on understanding how individual variability in gene expression causes genetic differences in drug responses and toxicity. My research employs a functional genomics-molecular genetics approach.

Read More

Carl Schmidt, MD

Carl Schmidt, MD, is a member of the Translational Therapeutics Program at OSUCCC – James, where his work focuses on surgical oncology. One of his recent collaborative studies indicates that extended lymphadenectomy (D2) can be done without increasing morbidity risk.

Read More

Manisha Shah, MD

Dr. Shah's research focuses on discovering new targeted therapies for patients with Neuroendocrine cancers, Thyroid cancers and Adrenal Cancers. Dr. Shah's lab offers phase II-III clinical trials in these types of cancers, conducts pre-clinical studies to learn types of drugs and combination of.

Read More

Alex Sparreboom, PhD

Dr. Sparreboom's research studies the contribution of solute carriers to chemotherapy-induced toxicity profiles, identifies chemical inhibitors of critical transporters, translates the findings to clinical trials in collaboration with scientists and oncologists, and ultimately improves the

Read More

Vishnu Baba Sundaresan, PhD

Dr. Sundaresan's research interests include: Bioderived Materials System - Concepts, Fabrication and Advanced Characterization and Modeling; Autonomous Self-healing Materials - Design, Fabrication and Advanced Characterization and Modeling; High Temperature Sensors - Advanced

Read More

Theodoros Teknos, MD

Dr. Teknos' research interests include: Cancer stem cell biology, cancer cell signalling, predictors of metastasis, predictors of treatment response, tumor/metastasis prevention.

Read More

Michael Tweedle, PhD

Dr. Tweedle’s research focuses on the creation of new molecularly targeted pharmaceuticals that are visualized in vivo via any diagnostic imaging technologies: CT, MRI, Nuclear, Ultrasound or Light imaging. Synthetic, analytical, and radio-chemistry, and cell and small animal biology and micro.

Read More

Meng Welliver, MD, PhD

The overarching research goal of Dr. Welliver’s lab is to understand the molecular underpinnings of subtypes of cancer and to design individualized, targeted therapy to augment the current standard treatment. Her laboratory training included DNA repair, cancer metabolism and cancer cell death.

Read More

Susanne Wells, PhD

Dr. Wells' research goal is to advance the understanding of both HPV-related and -unrelated SCC development, and to develop new approaches to the diagnosis and treatment of HPV as a major cause of cancer worldwide. Two major areas of investigation in the laboratory focus on: (1) Mechanisms.

Read More

Robert Wesolowski, MD

Dr. Wesolowski's research interests include breast cancer immunology, in particular myeloid-derived suppressor cells (MDSC) and early phase trials of experimental therapeutics. MDSC are important inhibitors of anti-tumor immune response.

Read More

Julia White, MD

Julia White, MD, is a member of the Translational Therapeutics Program at OSUCCC – James, where her research focuses on new methods to individualize breast radiation treatment. In particular, she works on developing and implementing new technologies such as prone, conformal, partial breast and.

Read More

Chadwick Wright, MD, PhD

Dr. Wright's research interests include (1) cancer imaging with clinical nuclear medicine techniques, (2) PET radioisotope-based optical imaging techniques (i. e.

Read More

Jianqiang Wu, MD, PhD

Dr. Wu's specializes in preclinical therapeutic trials on neurofibroma; cancer stem cell(s) in neurofibroma

Read More

Ronald Xu, PhD

Dr. Xu's research includes: (1) Ultrasound and near infrared dual-mode imaging of breast cancer (2) Multimodal microbubbles for cancer targeting and imaging (3) Heat sensitive microbubbles for cancer ablation margin imaging (4) Drug-loaded microbubbles for image-guided combinatory

Read More

Jack Yalowich, PhD

Jack Yalowich, PhD, is a member of the Translational Therapeutics Program at OSUCCC – James, where his research focuses on therapeutic treatment and prevention of cancers. In particular, he is exploring how to improve ability of the clinically effective anticancer agent etoposide (VP-16) in.

Read More

Alper Yilmaz, PhD

Dr. Yilmaz’ lab is developing a navigation system for assisting surgeons to visualize perioperative images and define better tumor margins in real time during the surgery. The system uses preoperative images to locate 3D cancer margins.

Read More

Jun Zhang, PhD

Dr. Zhang’s research includes the development of medical imaging methodologies for effective cancer therapies and improved medical drug development; evaluation of low dose PET and PET imaging acceleration for clinical oncologic PET/CT without compromising qualitative and quantitative image

Read More

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

OR

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

OR

Find a Scientific Publication

Search for Clinical Trials